|
|
Vaccine Detail
|
MSP3-CRM-Vac4All/ Alhydrogel® |
| Vaccine Information |
- Vaccine Name: MSP3-CRM-Vac4All/ Alhydrogel®
- Target Pathogen: Plasmodium spp.
- Target Disease: Malaria
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Antigen: MSP3 (Thera et al., 2022): merozoite surface protein 3. Presents on the surface of merozoites, forms a protein complex with MSP1, MSP6 and MSP7.The protein complex is bound to receptors during the invasion of erythrocytic cells. (Coelho et al., 2019)
- msp3
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
-
Adjuvant:
Alhydrogel® (Aw et al., 2021): an aluminium hydroxide (alum) wet gel suspension, increase the efficacy of the vaccine by the repository effect, pro-phagocytic effect, and activation of the pro-inflammatory NLRP3 pathway (He et al., 2015); CRM197(cross reacting material197) (Aw et al., 2021): a non-toxic mutant of diphtheria toxoid that used as glycoconjugate and improves vaccine immunogenicity (Aw et al., 2021).
- Immunization Route: Intramuscular injection (i.m.)
- Description: A protein-protein conjugate malaria and helminth TBV that uses a modified msp3 protein as an antigen and Alhydrogel (R) and CRM197 as adjuvant.
|
| Host Response |
|
Human Response
- Host age: 18-55 years old (Thera et al., 2022)
- Vaccination Protocol: Phase I, Randomised, Dose-Finding Single Center Study, not started.
Participants will be randomly put into three groups and will receive 3 doses of MSP3-CRM-Vac4All/ Alhydrogel®. Each group will receive different dose levels of MSP3-CRM-Vac4All/ Alhydrogel®: 3 µg, 10 µg, or 30 µg total MSP3-CRM197 conjugate protein (corresponding to 1, 3, 10 µg MSP3 protein). Participants will receive vaccination on day 1, day 28, and day 56 of the study. (Thera et al., 2022)
|
| References |
Aw et al., 2021: Aw R, Ashik MR, Islam AAZM, Khan I, Mainuddin M, Islam MA, Ahasan MM, Polizzi KM. Production and purification of an active CRM197 in Pichia pastoris and its immunological characterization using a Vi-typhoid antigen vaccine. Vaccine. 2021; 39(51); 7379-7386. [PubMed: 34774362].
Coelho et al., 2019: Coelho CH, Gazzinelli-Guimaraes PH, Howard J, Barnafo E, Alani NAH, Muratova O, McCormack A, Kelnhofer E, Urban JF Jr, Narum DL, Anderson C, Langhorne J, Nutman TB, Duffy PE. Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice. Vaccine. 2019; 37(8); 1038-1045. [PubMed: 30685251].
He et al., 2015: He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Human vaccines & immunotherapeutics. 2015; 11(2); 477-488. [PubMed: 25692535].
Thera et al., 2022: MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine (MSP3CRMV4All) [https://clinicaltrials.gov/ct2/show/NCT05197751?term=vaccine&cond=Malaria%2CFalciparum&draw=1&rank=10]
|
|
